SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Innate Pharma SA

Suletud

1.91 0.53

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.89

Max

1.91

Põhinäitajad

By Trading Economics

Sissetulek

57K

-25M

Müük

-8M

4.3M

Aktsiakasum

-0.3

Kasumimarginaal

-570.732

Töötajad

181

EBITDA

2.5M

-23M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+61.59% upside

Turustatistika

By TradingEconomics

Turukapital

29M

183M

Eelmine avamishind

1.38

Eelmine sulgemishind

1.91

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Innate Pharma SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. juuni 2025, 14:31 UTC

Tulu

New York State Retirement Fund Posts 5.84% Annual Investment Return

6. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. juuni 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. juuni 2025, 20:33 UTC

Tulu

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6. juuni 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6. juuni 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6. juuni 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6. juuni 2025, 16:35 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 16:34 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6. juuni 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. juuni 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. juuni 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6. juuni 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6. juuni 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6. juuni 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6. juuni 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. juuni 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6. juuni 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6. juuni 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6. juuni 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. juuni 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6. juuni 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6. juuni 2025, 14:12 UTC

Tulu

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6. juuni 2025, 14:09 UTC

Tulu

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Innate Pharma SA Prognoos

Hinnasiht

By TipRanks

61.59% tõus

12 kuu keskmine prognoos

Keskmine 3.103 EUR  61.59%

Kõrge 3.1 EUR

Madal 3.1 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Innate Pharma SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.91 / 2.1Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.